Umoja Biopharma

Umoja Biopharma is a clinical-stage biotechnology company specializing in the development of "off-the-shelf" cancer immunotherapies. Their goal is to expand the reach and effectiveness of CAR T-cell therapies, making them accessible to a wider range of patients. They achieve this through their innovative, integrated platform of technologies, including VivoVec™ (in vivo gene delivery), RACR/CAR™ (in vivo cell expansion/control), and TumorTag™ (targeting platform).

Umoja's approach utilizes a unique in vivo strategy, reprogramming the patient's immune system directly within their body. This eliminates the need for traditional ex vivo manufacturing processes, which are time-consuming, expensive, and can be challenging for patients to access. By building their own state-of-the-art lentiviral vector development and manufacturing facility, Umoja aims to provide more affordable, scalable, and efficient treatment options, empowering patients to live longer, healthier lives.

Umoja Biopharma provides a generous Paid Time Off policy, including end-of-year office closure, as well as an Employee Tuition Assistance Program, and flexible spending accounts for healthcare and dependent care. The company does not mention remote work opportunities or flexible schedules.

Umoja Biopharma offers a comprehensive benefits package to employees and their eligible dependents, including three medical plan options, comprehensive dental coverage including orthodontia, vision exam and hardware benefits, employer-provided life and disability insurance, a pretax health savings account with substantial Umoja contribution, flexible spending accounts for healthcare and dependent care, subsidized commuter costs and parking, an employee assistance program, a 401(k) retirement plan with a 100% match up to 6% employee deferral, an employer-funded lifestyle spending account, employee tuition assistance program, supplemental life insurance, and additional benefits and perks.

Umoja Biopharma's mission is to develop off-the-shelf immunotherapies that reprogram a patient's immune system to fight cancer, making these advanced treatments more accessible and effective for a broader range of patients. Their innovative platform technologies, including VivoVec, RACR/CAR, and TumorTag, work in tandem to generate and support an army of cancer-fighting T cells, potentially reducing adverse events and prolonging remissions for patients. They are committed to advancing the future of immunotherapy to change the lives of every patient bearing the burden of cancer.

Umoja Biopharma cultivates a collaborative and results-oriented culture, emphasizing unity, impact, and a dedication to finding solutions. They value diversity, recognizing that their team's strength lies in the unique skills and experiences of each individual. This fosters a sense of belonging and accountability, motivating employees to work together with confidence and optimism to advance their mission of improving cancer immunotherapy for all patients.

Umoja Biopharma is committed to fostering a diverse, equitable, and inclusive workplace. They recognize that their greatest asset is their team, and they are dedicated to building a diverse team of individuals who bring unique skills, backgrounds, and experiences to the company. They value the contributions of every member of their staff, regardless of their title, and believe that recognizing and leveraging their collective strengths, communicating with efficiency and care, and holding each other accountable are essential parts of their mission to extend the benefits of immunotherapy to every patient in need.